1625 related articles for article (PubMed ID: 34435953)
1. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
3. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
5. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
[TBL] [Abstract][Full Text] [Related]
6. Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.
Gan HH; Twaddle A; Marchand B; Gunsalus KC
J Mol Biol; 2021 Jul; 433(15):167051. PubMed ID: 33992693
[TBL] [Abstract][Full Text] [Related]
7. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
[TBL] [Abstract][Full Text] [Related]
8. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
9. Corilagin and 1,3,6-Tri-
Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
[TBL] [Abstract][Full Text] [Related]
10. Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
Kim S; Liu Y; Lei Z; Dicker J; Cao Y; Zhang XF; Im W
J Chem Theory Comput; 2021 Dec; 17(12):7972-7979. PubMed ID: 34856802
[TBL] [Abstract][Full Text] [Related]
11. Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants.
Laffeber C; de Koning K; Kanaar R; Lebbink JHG
J Mol Biol; 2021 Jul; 433(15):167058. PubMed ID: 34023401
[TBL] [Abstract][Full Text] [Related]
12. Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.
Wang R; Chen J; Gao K; Wei GW
Genomics; 2021 Jul; 113(4):2158-2170. PubMed ID: 34004284
[TBL] [Abstract][Full Text] [Related]
13. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.
Sinha S; Tam B; Wang SM
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062205
[TBL] [Abstract][Full Text] [Related]
14. Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex.
Ortuso F; Mercatelli D; Guzzi PH; Giorgi FM
J Biomol Struct Dyn; 2022 Sep; 40(14):6545-6555. PubMed ID: 33583326
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding.
Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Zhou S; Tuttle KS; Kim A; Li W; Dimitrov DS; Subramaniam S
Cell Rep; 2021 Dec; 37(12):110156. PubMed ID: 34914928
[TBL] [Abstract][Full Text] [Related]
16. Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability.
Verma J; Subbarao N
Virology; 2021 Sep; 561():107-116. PubMed ID: 34217923
[TBL] [Abstract][Full Text] [Related]
17. Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity.
Chakraborty S
Biochem Biophys Res Commun; 2021 Jan; 534():374-380. PubMed ID: 33272568
[TBL] [Abstract][Full Text] [Related]
18. Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2).
Istifli ES; Netz PA; Sihoglu Tepe A; Sarikurkcu C; Tepe B
J Biomol Struct Dyn; 2022; 40(23):12760-12771. PubMed ID: 34495817
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.
Xue S; Han Y; Wu F; Wang Q
Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
